Objectives: Non-small-cell lung cancer (NSCLC) patient survival depends on a number of factors, including early diagnosis and initiation of treatment. Standard treatment options for patients with NSCLC include surgery, radiation therapy, and chemotherapy. The objective of this study was to evaluate the impact that the initiation of timely treatment has on patient survival among a cohort of privately insured patients with NSCLC in South Carolina.
L ung cancer accounts for the largest number of cancer deaths among both men and women in the United States.
1,2 An estimated 158,040 deaths are attributable to lung and bronchus cancers and approximately 221,200 new cases, representing 13% of all cancer cases in the United States. 1 Non-small-cell lung cancer (NSCLC) is the most common type, accounting for approximately 85% of all lung cancer diagnoses.
3,4 The
• Initiation of treatment (surgery, radiation, and chemotherapy) within 42 days postdiagnosis does not prolong survival among patients with non-small-cell lung cancer (NSCLC).
• Patients with distant metastasized NSCLC receiving timely treatment experience a significantly shorter time of survival, in comparison with those receiving untimely care.
• Compared with white patients, black patients diagnosed as having localized NSCLC are experiencing significantly shorter survival times.
• In comparison with patients older than 74 years, those aged younger than 50 years and 50 to 64 years experience significantly greater survival times.
• Treatment for patients with NSCLC, including time-to-treat, should comply with evidence-based guidelines with consideration of patient comorbidities, genetic indicators, health behavior, cancer stage, and age when diagnosed.
5-year survival rate for patients diagnosed as having NSCLC at advanced stages (stages IIIA-IV) 5 is only 15%. 4 Treatment recommendations for NSCLC are dependent upon stage. Although surgery is the initial treatment in operable stages I through IIIA patients with nonresectable or borderline resectable NCSLC at initial presentation receive neoadjuvant (or definitive) chemoradiation to prolong survival. 6 Definitive chemotherapy is considered appropriate for stage IV patients with NSCLC only with good performance status. 7 The time interval between NSCLC diagnosis and initiation of treatment and its impact on patient survival varies in the literature. Kanarek et al 8 found that a longer interval from diagnosis to first surgery predicted worse overall survival, but found no significance at their threshold of treatment initiation of ≤41 days. Gould and associates 9 reported that in patients with malignant solitary pulmonary nodules, survival may improve when treatment is initiated promptly (within 83 days); however, timely care was not associated with better survival. Conversely, Gomez et al 10 found that timely treatment (<35 days) was associated with greater survival among patients diagnosed in the localized stage of NSCLC.
Treatment delays occur across all stages. A systematic review found that the time from referral to first respiratory specialist visit is longer than the recommended time interval (maximum of 7 days). 11 In addition, the median time from diagnosis to treatment initiation approached or exceeded the maximum 6-week time frame recommended as a standard goal. 11 Specific disease factors may account for these delays. In one study, military veterans diagnosed as having larger NSCLC tumors, those who experienced more pronounced symptoms, and those who underwent additional chest radiographic abnormalities were more likely to receive time-appropriate care. 9 Also, veterans diagnosed at earlier stages of NSCLC did not initiate treatment early when compared with those at more advanced stages. 12 Furthermore, treatment disparities among patients with lung cancer have been documented, and time intervals between symptom suspicion, diagnosis, and treatment vary by patient and hospital type. 13 Sex, race/ethnicity, and stage at diagnosis are independent factors contributing to disparities in the receipt of timely treatment. 14 The factors related to timeliness of care among privately insured patients with NSCLC and its impact on survival are not clearly documented. Our study addresses this gap in the literature by evaluating the timeliness of treatment initiation among a cohort of privately insured patients with NSCLC in South Carolina and its impact on patient survival. We hypothesized that patients receiving timely care via surgery, radiation, or chemotherapy exhibit better survival than their counterparts receiving untimely treatment.
Methods
Study subjects were retrospectively identified using the goldrated South Carolina Central Cancer Registry 15 16 Delay in seeking cancer care is defined as the number of days from the identification of the first symptom to visiting a physician, being diagnosed as having a condition, or beginning a regimen for treating the condition. The model interprets delay as an aggregate of underlying decision-making processes imposed by the patient. Treatment delay is the time between receiving medical attention and when care or treatment is initiated.
For the purposes of this study, we focused on examining potential delays that occur between diagnosis of NSCLC and initiation of treatment. Timely care was defined according to the RAND Corporation as a maximal time limit of 6 weeks (≤42 days) from diagnosis to treatment. 17 The mean and median survival times (in months) were calculated overall and by stage. Timely and untimely receipt of first treatment was analyzed to determine the impact of timeliness on patient survival, stratified by stage.
Kaplan-Meier curves and Cox proportional hazard models examined the effect of time between diagnosis and initiation of treatment (≤42 days vs >42 days) on risk of mortality. Estimates were evaluated for the sample population for four age groups: younger than 50 years, 50 to 64 years, 65 to 74 years, and 75 years and older. Cox proportional hazard models accounted for data censored as a result of SHP disenrollment and death. Three final models evaluated the factors associated with mortality, particularly the effect of timely treatment initiation stratified by stage. In addition to disease stage, histology type, and age at diagnosis, we controlled for patient's race (white or black) and sex (male or female). t tests and χ 2 tests examined statistical significance in the Cox proportional hazard models (α = 0.05). Statistical analysis was conducted using SAS version 9.4 (SAS Institute, Cary, NC). This study was approved by the University of South Carolina institutional review board.
Results
A total of 746 patients were included in the analysis. Of these, 53.9% were men and 77.4% were white (Table 1) . Almost half (44.1%) were diagnosed at the distant metastasis stage. Age at diagnosis, sex, race, stage at diagnosis, histology, year of diagnosis, and median education and income levels were significantly associated with receipt of timely care. Significant factors associated with receipt of untimely care were age at diagnosis, race, histology, and median educational level. The majority of patients across all factors received timely treatment. Table 2 shows the median and mean overall survival times and the receipt of timely or untimely care, stratified by disease stage. The overall median (and mean) survival times by stage were 36.0 (37.6), 25.0 (28.8), and 8.0 (13.9) months for localized, regional, and distant metastasis stages, respectively. The median (and mean) survival times by stage for patients receiving timely treatment were 36.0 (36.9), 24.5 (27.1), and 8.0 (12.4) months for localized, regional, and distant metastasis stages, respectively. The median (and mean) survival times for localized, regional, and distant metastasis patients receiving untimely 78 ) and those diagnosed as having non-small-cell carcinoma (HR 3.68) experienced shorter survival times compared with their white counterparts diagnosed as having adenocarcinoma. Sex was not a significant factor in predicting survival. Overall, initiation of timely treatment (any type) among localized patients with NSCLC was not significantly associated with patient survival. Table 4 represents the Cox proportional hazard model for factors associated with survival, including timeliness of first treatment, among regional (stages II-III) patients with NSCLC. Patients younger than 50 years (HR 0.10) and those aged 50 to 64 (HR 0.56) experienced greater survival time compared with their counterparts aged 75 years old and older. Sex, race, and cancer histology were not significantly associated with patient survival. Regional stage patients with NSCLC receiving timely treatment (any type) experienced a shorter survival time (HR 1.18); however, timely care among this group of patients was not significant (α = 0.05). Table 5 shows the Cox proportional hazard model for factors associated with survival, including timeliness of first treatment, among distant staged patients with NSCLC. Sex, race, age, and histology were not significant factors associated with patient survival. Compared with untimely treatment (any type), patients receiving timely treatment experienced a significantly shorter survival time (HR 2.2).
Discussion
In this cohort timely receipt of treatment, including surgery, radiation, or chemotherapy, across localized and regional stages of NSCLC does not appear to prolong survival. Moreover, we found that timely treatment is associated with decreased survival among patients with distant metastasis. Although timely treatment did not appear to prolong survival in patients at any cancer stage, a potential confounding factor leading to the actual diagnosis of NSCLC is the presence of symptoms. Whereas many localized and regional staged patients have no symptoms on presentation, later-stage patients with NSCLC are noted to be more symptomatic. According to Hamilton et al, 18 seven symptoms (hemoptysis, loss of weight, loss of appetite, dyspnea, thoracic pain, fatigue, and cough) were noted to correlate with the presence of lung cancer. Indeed, the presence of two symptoms markedly increases the risk of cancer in the patient population studied. Walter et al 19 reported that the presence of symptoms, especially more than one symptom, is related to more advanced stages of lung cancer. This being said, the lack of symptoms in early-stage lung cancer may lead to a longer lead time to the initial diagnosis of cancer. 20 This phenomenon may contribute to a bias affecting the reported time to initial treatment in our study. Although the symptom lead time could not be determined in our study, it could account for the prolonged survival in the more advanced cancers including distant-stage patients with untimely treatment. This patient population likely has multiple advanced symptoms leading to the diagnosis of the distant-staged NSCLC before their timely treated distant-stage counterparts. Although treatment may not have been within 42 days, as a result of symptom lead time, it still could have occurred before initiation of treatment in the timely treated cohort. Indeed, with the initiation of lung cancer screening as recommended by the US Preventive Services Task Force starting in 2015, the symptom lead time may eventually become obsolete because more asymptomatic high-risk patients will be screened to detect cancer at earlier stages. 21 In addition, aggressive cases of distant metastasis may have been more likely to receive timely care than their counterparts with fewer distant-affected organs. Patients in our cohort receiving timely care were more likely to be diagnosed as having advanced stages (regional and distant metastasis) of NSCLC, which is consistent with previous studies. 12, 22 Because of the worse prognosis for these patients, timeliness of treatment may be less effective. Our findings are consistent with previous studies showing that timely initiation of treatment has no significant impact on patient survival. 9, 13, 23, 24 Contrary to our findings, Gomez et al 10 found that timely treatment (<35 days) improved survival for patients at the local and distant stages of NSCLC; however, improved survival was only found among patients who survived 1 year or longer.
Our findings also indicated that black patients with localized NSCLC have significantly shorter survival time, compared with their white counterparts. Part of this finding may be because whites represented almost 80% of the cohort; however, evidence suggests that disparities exist in treatment initiation by race/ethnicity, with minorities experiencing longer treatment delays. 14, 25 An array of factors is considered in choosing relevant treatment options for patients with NSCLC, including prognosis. Studies indicate that accurate staging for NSCLC is critical for predicting prognosis and determining appropriate therapy. 26, 27 Age is another determining factor for NSCLC treatment. Most older adult patients diagnosed as having advanced stages of NSCLC do not receive chemotherapy, yet chemotherapy may improve survival for these patients. [28] [29] [30] Study findings indicate that timely treatment initiation holds the most benefit for patients younger than 65 years, diagnosed at localized and regional stages of the disease.
In addition to accuracy of staging and age as key factors for recommending treatment for patients with NSCLC, comorbidities, behavior, and quality of life also play a major role. Chronic obstructive pulmonary disease along with respiratory symptoms and decreased pulmonary function are prevalent among patients diagnosed as having lung cancer, especially among men, and greatly affect the overall quality of life and long-term survival of patients with NSCLC. 31, 32 Patients with such comorbidities diagnosed in the earlier stages of NSCLC are not considered to be the best candidates for surgery because of the possibility of exacerbating comorbidities after surgical resection and further decreasing quality of life and survival. 33, 34 Instead, many patients with early-stage NSCLC undergo radiation therapy, specifically stereotactic body radiotherapy, which may become the standard of care for patients with early-stage NSCLC in the near future. 35, 36 Evidence suggests that stereotactic body radiotherapy is highly effective in improving survival and containing localized disease among patients with inoperable early-stage NSCLC and may even be superior to surgical outcomes among operable NSCLC cases. [37] [38] [39] Moreover, genetic mutations to the epidermal growth factor receptor (EGFR) and the anaplastic lymphoma kinase (ALK) can appear in some NSCLC cases, influencing NSCLC prognosis, treatment allocation, and, ultimately, patient survival. 37, 38 Among patients with NSCLC with mutated EGFR genes, the administration of gefitinib (orally administered tyrosine kinase inhibitor of EGFR) or chemotherapy significantly prolongs survival. [40] [41] [42] Survival among patients with NSCLC with a genetically rearranged ALK gene benefits from treatment in the form of crizotinib (orally administered tyrosine kinase inhibitor targeting the ALK gene) 43 and is even superior to chemotherapy for patients with advanced stages of NSCLC. 44 This evidence suggests the importance of biological markers as an indicator of NSCLC prognosis and treatment initiation, which we were unable to assess in the present study.
Improving survival among patients with NSCLC also depends upon health behaviors, including smoking cessation for current smokers. 27 Smoking at the time of diagnosis significantly shortens patient survival, but patients who quit smoking within the first 6 months following diagnosis experience better performance status across all ages, races, sex, stages, and treatment therapies. 45, 46 Delaying care for cancer patients long enough for them to quit smoking before initiation of treatment may improve outcomes. 47 From a patient perspective, delays in seeking care and treatment can stem from a number of factors, including symptom awareness and personal decisions in seeking care, as well as from structural issues, including wait times for appointments and treatment. 16 In addition, a common reason for delaying treatment in patients with NSCLC is the need for multiple diagnostic tests and consultations with pulmonologists, oncologists, and other providers. 11 All of these factors can influence the time to treatment initiation, ultimately influencing survivorship.
This study has several limitations. First, causality cannot be determined in this retrospective cross-sectional study. Second, the study sample was limited to patients living in South Carolina who were covered under the SHP before diagnosis; this may restrict the generalizability of findings to other populations. Third, we did not examine earlier diagnosis and its impact on survival, nor were we able to account for other treatment characteristics such as intensity of the recommended full course of treatment or patient adherence to all recommended treatments. Fourth, we were unable to calculate symptom lead time or the presence of symptoms and the effect of specialty visits on patient survival. In addition, we were unable to classify patients who were staged following lobectomy. Treatment guidelines according to NSCLC stage are complex; therefore, we could not analyze a timeliness effect according to stagespecific guidelines because of the limited information on medical operability of tumors, biopsy findings, and other clinical factors that dictate the full treatment course for patients with NSCLC diagnosed at different stages. Lastly, there are many phases of NSCLC care in which delays can occur, including treatment consultations and diagnostic testing. Each phase of delay is potentially critical and further research should be undertaken to ascertain its magnitude of importance and impact on patient outcomes. Qualitative data from healthcare providers also should be collected to better understand precursors to delays in NSCLC care and diagnosis. Finally, future research should examine both the effects of early diagnosis and treatment on survival in patients with NSCLC and the impact of comorbidities and preexisting conditions as well as socioeconomic factors on treatment initiation and survival.
At the same time, this study has several strengths. The study sample represents a unique cohort from South Carolina, which has a high proportion of both rural and minority populations with diverse socioeconomic backgrounds. We also note that this insured cohort represents approximately 11% (433,576) of the population in South Carolina. 48 In addition, we were able to leverage the combined attributes of cancer registry and administrative claims data. In this way, we used high-validity diagnosis data (from the registry) and high-validity treatment data (from administrative data). We believe that this is an important distinction that is a methodological improvement over some of the previous studies.
Conclusions
Initiation of timely treatment for all treatment types was found not to be associated with greater survival time among a retrospective cohort of patients diagnosed as having NSCLC. The finding that timely treatment was associated with shorter survival time among patients in the distant metastasis stage of NSCLC was counterintuitive to our hypothesis. Before modifying NSCLC treatment guideline recommendations based on the findings of our study, it is imperative that the medical community rule out all possible confounders including but not limited to comorbidity, presence of symptoms and genetic indicators, cancer stage, prognosis, age at time of diagnosis, and patient health behavior.
